P/E ratio for GlaxoSmithKline (GSK)

P/E ratio history for GlaxoSmithKline from 2001 to 2023

PE ratio at the end of each year

P/E ratio for similar companies or competitors

Company	P/E ratio	P/E ratio differencediff.	Country
AstraZeneca AZN	33.1	240.56%	🇬🇧 UK
Pfizer PFE	13.7	41.37%	🇺🇸 USA
Merck MRK	55.0	466.20%	🇺🇸 USA
Novartis NVS	28.0	187.78%	🇨🇭 Switzerland
Sanofi SNY	15.2	56.78%	🇫🇷 France
Teva Pharmaceutical Industries TEVA	-8.46	-187.12%	🇮🇱 Israel
Dynavax Technologies DVAX	14.3	47.24%	🇺🇸 USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.